However, due to low expression of CD16 but significant expression of NKp46 on tumor-associated NK cells (Figures 1B, 5A), the use of novel trifunctional NK cell engagers simultaneously triggering NKp46 and CD16 on NK cells, and a tumor antigen on CRC cells (e.g. EGFR), could represent a more suitable approach to effectively control tumor growth (39, 40) (summarized in Figure 7). The gene discussed is NCR1; the disease is colorectal carcinoma.